A Phase III, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients
Administered By
Awarded By
Contributors
- ElMallah, Mai Principal Investigator
Start/End
- November 20, 2017 - December 31, 2020